FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

The Harvard Drug Group Memantine Hydrochloride Extended-release Recall

Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dos…

The Harvard Drug Group · Livonia, MI

Risk level
Class III
Reported by FDA
Feb 26, 2020
Recall ID
D-0844-2020
Check your lot numberHow we source this data

Summary

The Harvard Drug Group recalled Memantine Hydrochloride Extended-release starting Dec 13, 2019. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0844-2020 on Feb 26, 2020. Reason: Failed Dissolution Specifications: High out of specification result observed at stability studies. Status: Terminated.

Why it was recalled

Failed Dissolution Specifications: High out of specification result observed at stability studies.

Product description

Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 United States; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6735-61

Lot numbers, UPCs & expiration codes

Lot# M02465D

Where it was sold

U.S.A. Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0844-2020
Classification
Class III
Status
Terminated
Recall initiated
Dec 13, 2019
FDA report date
Feb 26, 2020
Quantity
246 Cartons
Recall type
Voluntary: Firm initiated
Recalling firm
The Harvard Drug Group

Original FDA data

Every field from FDA enforcement report D-0844-2020, exactly as published.

Show all FDA fields
City
Livonia
State
MI
Status
Terminated
Country
United States
Event ID
84955
Address
17177 N Laurel Park Dr Ste 233
Code information
Lot# M02465D
Postal code
48152-3951
Report date
Feb 26, 2020
Product type
Drugs
Recall number
D-0844-2020
Classification
Class III
Recalling firm
The Harvard Drug Group
Product quantity
246 Cartons
Termination date
Nov 4, 2020
Reason for recall
Failed Dissolution Specifications: High out of specification result observed at stability studies.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 United States; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6735-61
Distribution pattern
U.S.A. Nationwide
Recall initiation date
Dec 13, 2019
Initial firm notification
Letter
Center classification date
Feb 14, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0844-2020, published Feb 26, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls